US20140322172A1 - Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof - Google Patents

Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof Download PDF

Info

Publication number
US20140322172A1
US20140322172A1 US14/363,150 US201214363150A US2014322172A1 US 20140322172 A1 US20140322172 A1 US 20140322172A1 US 201214363150 A US201214363150 A US 201214363150A US 2014322172 A1 US2014322172 A1 US 2014322172A1
Authority
US
United States
Prior art keywords
strain
bacterial cell
lipid metabolism
lactobacillus
metabolism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/363,150
Other languages
English (en)
Inventor
Futoshi Nakamura
Nobuhisa Ashida
Yu Ishida
Shigeru Fujiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Group Holdings Ltd
Original Assignee
Calpis Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calpis Co Ltd filed Critical Calpis Co Ltd
Assigned to CALPIS CO., LTD. reassignment CALPIS CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASHIDA, NOBUHISA, FUJIWARA, SHIGERU, NAKAMURA, FUTOSHI, ISHIDA, YU
Publication of US20140322172A1 publication Critical patent/US20140322172A1/en
Assigned to ASAHI GROUP HOLDINGS, LTD. reassignment ASAHI GROUP HOLDINGS, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CALPIS CO., LTD.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A23L1/3014—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/115—Amylovorus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/145—Gasseri
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Definitions

  • the present invention relates to a lipid metabolism and/or sugar metabolism improver comprising a bacterial cell of the genus Lactobacillus or the genus Bifidobacterium or a treated product thereof having a high ability to activate Peroxisome Proliferator Activated Receptors (PPARs) ⁇ and ⁇ , which are deeply involved with metabolic syndrome.
  • the present invention also relates to a functional food or a pharmaceutical composition comprising such a lipid metabolism and/or sugar metabolism improver for treating or preventing diseases or disorders associated with the lipid metabolism and sugar metabolism.
  • Metabolic syndrome is defined as multiplex conditions of visceral fat type obesity in combination with hyperlipidemia, hyperglycemia, hypertension, and the like, and has a high risk of developing arteriosclerotic diseases.
  • PPARs associated with the lipid and sugar metabolisms are attracting attentions.
  • PPARs are nuclear transcriptional regulators.
  • PPAR ⁇ that is highly expressed mostly in the liver and small intestine causes fat burning by promoting the ⁇ oxidation of fatty acids and also exhibits the action of promoting HDL cholesterol production.
  • PPAR ⁇ highly expressed mostly in fat tissues, improves the insulin resistance by regulating the fat cell differentiation in the fatty tissues, suppressing the secretion of an inflammation factor TNF- ⁇ from fat cells, and promoting the secretion of adiponectin.
  • a fibrate preparation which is a PPAR ⁇ ligand agent and a thiazolidin derivative which is a PPAR ⁇ ligand agent are known as pharmaceutical products for activating PPARs, but adverse effects thereof are concerned when taken for an extended period of time.
  • Patent Documents 1 to 4 it is documented that bacterial cells of lactic acid bacteria or Bifidobacteria and cultured products thereof (culture broth, culture supernatant, concentrated products thereof, and the like) are effective for improving the lipid metabolism, for example, reducing blood cholesterol, reducing body fat or visceral fat, or the like.
  • Patent Documents 1 to 4 they did not activate PPARs or did not have satisfactory effects.
  • Patent Document 5 an organic solvent extract of a lactic acid bacterium activates PPAR (Patent Document 5) but this was only to show the activity of PPAR ⁇ , and the effect thereof was not sufficient, either.
  • Non Patent Document 1 the activity of liver PPAR ⁇ in a model mouse with alcoholic liver disease was examined when Lactobacillus brevis SBC8803 strain was administered to the mouse, and, as a result, the activation remained unchanged (Non Patent Document 1), and it is documented when a mixture of a plurality of lactic acid bacteria was administered to a steatohepatitis model which was on a high fat diet, the PPAR ⁇ activity whose expression had been reduced due to the high fat diet was recovered (Non Patent Document 2), but no descriptions regarding PPAR ⁇ are found.
  • a material capable of activating both PPAR ⁇ and PPAR ⁇ is desired.
  • An object of the present invention is to provide a means which has a highly agonistic activation of both PPAR ⁇ and PPAR ⁇ and is effective and safe for improving both lipid metabolism and/or sugar metabolism.
  • Another object of the present invention is to provide a means for treating or preventing diseases or disorders associated with lipid metabolism disorders and/or sugar metabolism disorders.
  • the present inventors carried out extensive studies to solve the above problems and have now accidentally found that a plurality of lactic acid bacteria strains or Bifidobacteria strains, which strongly activate both PPAR ⁇ and PPAR ⁇ .
  • Lactobacillus amylovorus CP1563 strain has now been found as the highly active strains.
  • the present invention encompasses the following embodiments.
  • PPAR peroxisome proliferator activated receptor
  • PPAR peroxisome proliferator activated receptor
  • bacterial cell or the treated product thereof according to any one of the above (1) to (3), wherein the bacterial cell is the CP1563 strain (Accession Number FERM BP-11255) or CP1562 strain (Accession Number FERM BP-11379) or a mutant or bred strain thereof, or a mutant or bred strain of CP2305 strain (Accession Number FERM BP-11331).
  • a lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell, a treated product thereof, or a mixture thereof having dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR) ⁇ and a peroxisome proliferator activated receptor (PPAR) ⁇ , wherein the bacterial cell is preferably selected from the genus Lactobacillus and the genus Bifidobacterium.
  • PPAR peroxisome proliferator activated receptor
  • PPAR peroxisome proliferator activated receptor
  • a lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell selected from bacteria belonging to the genus Lactobacillus and the genus Bifidobacterium , a treated product thereof, or a mixture thereof having dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR) ⁇ and a peroxisome proliferator activated receptor (PPAR) ⁇ .
  • a peroxisome proliferator activated receptor PPAR
  • PPAR peroxisome proliferator activated receptor
  • the bacterial cell is Lactobacillus amylovorus CP1563 strain (Accession Number FERM BP-11255) or Lactobacillus amylovorus CP1562 strain (Accession Number FERM BP-11379) or Lactobacillus gasseri CP2305 strain (Accession Number FERM BP-11331), or a mutant or bred strain thereof.
  • the lipid metabolism and/or sugar metabolism improver according to any one of the above (6) to (11), which further comprises a carrier or an excipient used for foods or beverages or pharmaceutical drugs.
  • a food or beverage comprising the lipid metabolism and/or sugar metabolism improver according to any one of the above (6) to (12) as a food additive.
  • a pharmaceutical composition for use in preventing, improving, or treating a lipid metabolism disorder and/or sugar metabolism disorder comprising as an active ingredient the lipid metabolism and/or sugar metabolism improver according to any one of the above (6) to (12).
  • a process for producing a food or beverage having a lipid metabolism and/or sugar metabolism improving effect comprising adding the lipid metabolism and/or sugar metabolism improver according to any one of the above (6) to (12) to a food or beverage.
  • Lactobacillus amylovorus CP1563 strain (Accession Number FERM BP-11255), Lactobacillus amylovorus CP1562 strain (Accession Number FERM BP-11379), Lactobacillus gasseri CP2305 strain (Accession Number FERM BP-11331), or a mutant or bred strain thereof, a treated product thereof, or a mixture thereof in the production of the lipid metabolism and/or sugar metabolism improver according to any one of the above (6) to (12).
  • Lactobacillus amylovorus CP1563 strain (Accession Number FERM BP-11255) or Lactobacillus amylovorus CP1562 strain (Accession Number FERM BP-11379), or a mutant or bred strain thereof, or a mutant or bred strain of Lactobacillus gasseri CP2305 strain (Accession Number FERM BP-11331) for use in imparting a lipid metabolism and sugar metabolism improving effect.
  • Lactobacillus amylovorus CP1563 strain (Accession Number FERM BP-11255) or Lactobacillus amylovorus CP1562 strain (Accession Number FERM BP-11379) or a mutant or bred strain thereof, or a mutant or bred strain of Lactobacillus gasseri CP2305 strain (Accession Number FERM BP-11331).
  • the present invention encompasses the contents described in the specifications and/or drawings of Japanese Patent Application Nos. 2011-268313 and 2012-067187, to which the present application claims priority.
  • bacterial cells such as Lactobacillus amylovorus, Lactobacillus gasseri , or the like, comprising Lactobacillus amylovorus CP1563 strain, Lactobacillus amylovorus CP1562 strain, Lactobacillus gasseri CP2305 strain, and the like, or a treated product thereof, which have dual-agonist activities to both PPAR ⁇ and PPAR ⁇ , are taken, fat burning and HDL cholesterol production are promoted and the lipid metabolism is improved by strong activation of PPAR ⁇ , and further the sugar metabolism and the insulin resistance are improved by activation of PPAR ⁇ , whereby the metabolic syndrome can be prevented or improved.
  • bacterial cells such as Lactobacillus amylovorus, Lactobacillus gasseri , or the like, comprising Lactobacillus amylovorus CP1563 strain, Lactobacillus amylovorus CP1562 strain, Lactobacillus gasseri CP2305 strain, and the like
  • FIG. 1 is a graph showing a dose dependent effect (on HDL-cholesterol) of a lactic acid bacterium in diet induced obese model. * and ** show the statistical significance.
  • FIG. 2 is a graph showing a dose dependent effect (on arteriosclerotic index) of a lactic acid bacterium in diet induced obese model. ** shows the statistical significance.
  • FIG. 3 is a graph showing an antimetabolic syndrome effect of a lactic acid bacterium in diet induced obese model.
  • A is for HDL-cholesterol
  • B is for LDL-cholesterol
  • C is for triglyceride
  • D is for arteriosclerotic index
  • E is for high molecular adiponectin
  • F is for visceral fat weight, respectively.
  • *, **, *** and + show the statistical significance.
  • FIG. 4 is a graph showing the fat metabolism improving effect when the disrupted cells of Lactobacillus amylovorus CP1563 strain were administered to healthy human volunteers.
  • the comparative control did not contain the disrupted cells of CP1563 strain.
  • the influences to or effects on A: body weight, B: body fat ratio, C: BMI, D: body temperature, E: subcutaneous fat, and F: visceral fat, respectively, are shown.
  • the present invention provides a fat metabolism and/or sugar metabolism improver comprising, as an active ingredient, preferably a bacterial cell of a lactic acid producing bacterium, more preferably a bacterial cell selected from the genus Lactobacillus and the genus Bifidobacterium , a treated product thereof, or a mixture thereof having dual-agonist activities to peroxisome proliferator activated receptor (PPAR) ⁇ and peroxisome proliferator activated receptor (PPAR) ⁇ .
  • PPAR peroxisome proliferator activated receptor
  • PPAR peroxisome proliferator activated receptor
  • the present invention also provides the above-mentioned bacterial cell or treated product thereof as described below.
  • the “PPAR ⁇ agonist activity” used herein promotes the fat burning and the HDL cholesterol production and improves the fat metabolism.
  • diseases such as hyperlipidemia, dyslipidemia, obesity, hypercholesterolemia, hypertriglyceridemia, arteriosclerosis, inflammatory symptoms, and the like, can be prevented, improved or treated.
  • the “PPAR ⁇ agonist activity” used herein suppresses the secretion of the inflammation factor TNF- ⁇ from fat tissues and promotes the secretion of adiponectin, thereby improving both of the insulin resistance and the sugar metabolism.
  • diseases such as hyperglycemia, non-insulin-dependent diabetes mellitus, arteriosclerosis, cardiac hypertrophy, ischemic heart disease, or the like, can be prevented, improved or treated.
  • the fat metabolism and/or sugar metabolism improver of the present invention is also effective for preventing, improving or treating so-called the metabolic syndrome including obesity and diabetes by having both PPAR ⁇ agonist activity and PPAR ⁇ agonist activity.
  • the PPAR ⁇ agonist activity in the lipid metabolism and/or sugar metabolism improver of the present invention is a positive activity of typically 70 or more, preferably 80 or more, further preferably 90 or more, most preferably 100 or more, for example, 110 or more, 120 or more, 130 or more, or 140 or more, relative to negative control activity of 0 and positive control activity of 100 as measured by PPAR ⁇ reporter assay (see Examples later).
  • the negative control activity of 0 and positive control activity of 100 as measured by PPAR ⁇ reporter assay used herein is defined in Definition 1 to be described later.
  • the PPAR ⁇ agonist activity in the lipid metabolism and/or sugar metabolism improver of the present invention is a positive activity of exceeding 0, for example, 2 or more, 4 or more, 5 or more, preferably 10 or more, 20 or more, further preferably 30 or more, 35 or more, most preferably 40 or more, relative to negative control activity of 0 and positive control activity of 100 as measured by PPAR ⁇ reporter assay (see Examples later).
  • the negative control activity of 0 and positive control activity of 100 as measured by PPAR ⁇ reporter assay used in the present invention is defined in Definition 2 to be described later.
  • the bacterial cell having the dual-agonistic activities to PPAR ⁇ and PPAR ⁇ is a bacterial cell selected from bacteria belonging to the genus Lactobacillus and the genus Bifidobacterium , a treated product thereof, or a mixture thereof.
  • Such a bacterial cell includes, but is not limited to, Lactobacillus amylovorus, Lactobacillus gasseri, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium pseudolongum, Bifidobacterium magnum, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus fermentum, Lactobacillus brevis, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus johnsonii
  • Preferable cell strains are Lactobacillus amylovorus strains (e.g., CP1563 strain; Accession Number FERM BP-11255, CP1562 strain; Accession Number FERM BP-11379), Lactobacillus gasseri strains (e.g., CP2305 strain; Accession Number FERM BP-11331), Bifidobacterium infantis strains, Bifidobacterium breve strains, or mutants or bred strains thereof, and most preferable strains are CP1563 strain (Accession Number FERM BP-11255) or mutants or bred strains thereof.
  • CP1563 strain accesion Number FERM BP-11255
  • Lactobacillus amylovorus CP1563 strain and Lactobacillus amylovorus CP1562 strain are lactic acid bacteria derived from the human intestinal tract. These bacterial strains or treated products thereof are validated to have the fat metabolism and/or sugar metabolism improving action in Examples later, and available from the National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary (1-1-1 Higashi, Tsukuba, Ibaraki, Tsukuba Central 6, 305-8566 Japan).
  • the lactic acid producing bacteria usable in the present invention preferably bacterial species selected from the genus Lactobacillus and the genus Bifidobacterium , can be grown and recovered by incubating under typically employed conditions using media commonly used for incubating bacterial species such as Lactobacillus (a lactic acid bacterium) and Bifidobacterium.
  • a culture medium typically contains a carbon source, a nitrogen source, inorganic salts, and the like, and may be a natural medium or synthetic medium as long as it can efficiently incubate the above bacterial species.
  • the usable carbon source include lactose, glucose, sucrose, fructose, galactose, molasses, and the like
  • examples of the usable nitrogen source include organic nitrogen-containing products such as casein hydrolysate, whey protein hydrolysate, soy protein hydrolysate, yeast extract, meat extract, and the like.
  • the inorganic salts include phosphate, sodium, potassium, magnesium, manganese, iron, zinc, and the like.
  • suitable media for culturing lactic acid bacteria include MRS liquid medium, GAM medium, BL medium, Briggs Liver Broth, animal milk, skim milk, milk whey, and the like.
  • sterilized MRS medium can be used.
  • a medium composed only of food materials and food additives can also be prepared and used.
  • tomato juice, carrot juice, other vegetable juices, or apple juice, pineapple juice, grape juice, or the like can also be used.
  • the incubation is carried out under anaerobic conditions at 20° C. to 50° C., preferably 25° C. to 42° C., more preferably about 37° C.
  • the temperature condition can be adjusted using an incubator, mantle heater, jacket, or the like.
  • the anaerobic condition refers to an environment of low oxygen at which the bacterium can grow, and the anaerobic condition can be achieved by, for example, using an anaerobic chamber, anaerobic box or a sealed container or bag containing an oxygen absorber, or simply sealing a culture container.
  • the culture mode is stationary culture, shaking culture, tank culture, or the like.
  • the incubation time is not limited but may be, for example, 3 hours to 96 hours.
  • the medium pH at the time of initiating incubation is preferably maintained, for example, from 4.0 to 8.0.
  • Lactobacillus amylovorus CP1563 strain and Lactobacillus amylovorus CP1562 strain are used as lactic acid bacteria, they may be inoculated in food grade media for lactic acid bacteria and incubated at about 37° C. overnight (for about 18 hours).
  • the obtained cultured product of a lactic acid bacterium may be used without further treatment, or may be roughly purified as necessary by the centrifugal separation and/or the solid liquid separation or sterilization procedure by filtration, or the like, may be carried out.
  • the lactic acid bacteria used in the present invention may be either wet bacterial cell or dry bacterial cell.
  • these bacterial cells are stationarily cultured in MRS medium until the logarithmic growth phase, subsequently washed in sterilized physiological saline or sterilized water, and treated with 50 to 500 ⁇ g/ml of a mutagen such as N-methyl-N′-nitro-N-Nitrosoguanidine (NTG) at 30 to 37° C. for 30 to 60 minutes in the same sterilized physiological saline or sterilized water to obtain a mutant strain.
  • a mutagen such as N-methyl-N′-nitro-N-Nitrosoguanidine (NTG)
  • EMS ethylmethane sulfonate
  • fluorouracil 5 -FU
  • Taxonomically the microbiological characteristics of an obtained bacterial strain can be verified by, for example, examining the homology of a 16S rRNA gene nucleotide sequence, examining the DNA-DNA homology by DNA-DNA hybridization with the standard strain, examining the sugar utilizing properties, or the like.
  • Examples of the treated product of a bacterial cell used herein include, but are not limited to, destructed products of a bacterial cell extracts of a bacterial cell, dried products, frozen products, water-dispersed products, emulsified products, or the like, thereof.
  • the destructed products of a bacterial cell are those obtained by the destruction treatment such as disrupting (in this case a bacterial cell disrupted product is obtained), grinding, enzymatically treating, chemically treating, dissolving, or the like, and the form of the destructed product of a bacterial cell is not limited to a specific one as long as the bacterial cell has dual-agonistic activities to peroxisome proliferator activated receptor (PPAR) ⁇ and peroxisome proliferator activated receptor (PPAR) ⁇ .
  • PPAR peroxisome proliferator activated receptor
  • PPAR peroxisome proliferator activated receptor
  • the destruction of bacterial cell can be carried out, using techniques and devices known in the art, by, for example, physical disruption, enzymatic dissolution treatment, or the like.
  • the physical disruption may be carried out in either wet mode (processed in the form of bacterial cell suspension) or dry mode (processed in the form of bacterial cell powder), and can be carried out by stirring using a homogenizer, ball mill, bead mill, DYNO-mill, Planetary mill, or the like; by compressing using a jet mill, French press, cell disruptor, or the like; or by filtering using a filter.
  • the cell wall of bacterial cell can be destructed using an enzyme such as lysozyme, or the like.
  • the bacterial cell is disrupted by treating a suspension of a lactic acid bacterium 1 to 7 times (e.g., 3 to 5 times) in a known DYNO-MILL cell disruptor (DYNO-MILL disrupting device, or the like), using glass beads, at a circumferential speed of 10.0 to 20.0 m/s (e.g., about 14.0 m/s) and a processing flow rate of 0.1 to 10 L/10 min (e.g., about 1 L/10 min) at a disrupting tank temperature of 10 to 30° C. (e.g., about 15° C.).
  • DYNO-MILL disrupting device DYNO-MILL disrupting device, or the like
  • the bacterial cell is disrupted by, for example, treating a suspension of a lactic acid bacterium 1 to 30 times (e.g., 10 times) in a known wet jet mill cell disruptor (JN20 Nano Jet Pal, or the like) at a discharge pressure of 50 to 1000 MPa (e.g., 270 MPa) and a processing flow rate of 50 to 1000 (e.g., 300) ml/min.
  • a suspension of a lactic acid bacterium 1 to 30 times e.g., 10 times
  • JN20 Nano Jet Pal JN20 Nano Jet Pal, or the like
  • the bacterial cell can also be disrupted by treating lactic acid bacterium cell powder in a known dry planetary mill cell disruptor (GOT5 Galaxy 5, or the like) in the presence of various balls (e.g., 10 mm zirconium ball, 5 mm zirconium ball, 1 mm aluminum ball) at a rotation number of 50 to 10,000 rpm (e.g., 240 rpm, 190 rpm, 110 rpm) for 30 minutes to 20 hours (e.g., 5 to 10 hours).
  • various balls e.g., 10 mm zirconium ball, 5 mm zirconium ball, 1 mm aluminum ball
  • the bacterial cell may also be disrupted by treating lactic acid bacterium cell powder 1 to 10 times (e.g., 1 time) in a known dry jet mill cell disruptor (Jet O-mizer, or the like) at a supplying rate of 0.01 to 10000 g/min (e.g., 0.5 g/min) and a discharge pressure of 1 to 1000 kg/cm 2 (e.g., 6 kg/cm 2 ).
  • a dry jet mill cell disruptor Jet O-mizer, or the like
  • the disrupted product of a bacterial cell still shows the effect even when the bacterial cell has just a hall, but it is desirable to prepare the disrupted product so that the average major axis of destructed bacterial cells is 90% or less of before the destruction treatment.
  • the average major axis of destructed bacterial cells may sometimes be close to 0%.
  • the bacterial cell can be destructed so that the average major axis of destructed bacterial cells in the disrupted product is 90% or less, preferably 80% or less, 70% or less, 60% or less, or 50% or less, more preferably 40% or less, 30% or less, or 20% or less, of before the disruption.
  • the bacterial cell and/or the disrupted product thereof can be dried to form a powder product or a granulated product.
  • Specific drying methods include, but are not particularly limited to, spray-drying, drum drying, vacuum drying, freeze-drying, and the like, and these methods may be employed alone or in combination. At this time, a commonly used carrier or excipient may be added where needed.
  • the bacterial cell extract can be obtained by extraction treatment of the bacterial cell or the disrupted product thereof with water, an organic solvent or a mixed solvent, optionally in combination, and recovering a fraction containing the active ingredient having the agonistic activities to PPAR ⁇ and PPAR ⁇ .
  • the organic solvent is a polar solvent, nonpolar solvent, or a mixed solvent thereof
  • the polar solvent include alcohols such as methanol, ethanol, and propanol, acetone, acetonitrile, dioxane, DMSO, DMF, and the like
  • examples of the nonpolar solvent include ethers such as diethyl ether, hydrocarbons such as hexane, heptane, and the like, alkyl halides such as dichloromethane, chloroform, and the like.
  • the active ingredient of the present invention may have a property which is easily extracted by a nonpolar organic solvent such as diethyl ether, or the like, and may be partially extracted also by a polar organic solvent such as ethanol, acetonitrile, DMSO, or the like.
  • a nonpolar organic solvent such as diethyl ether, or the like
  • a polar organic solvent such as ethanol, acetonitrile, DMSO, or the like.
  • the fact that the extract has the agonistic activities to PPAR ⁇ and PPAR ⁇ can be confirmed by known assay techniques such as PPAR ⁇ reporter assay, PPAR ⁇ reporter assay, and the like, as described in Examples later.
  • the bacterial cell extract of the present invention also encompasses concentrated products or residues obtained by concentrating using a vaporizer such as an evaporator, or the like, preferably those obtained by removing the solvent.
  • a component or a fraction having the lipid metabolism and sugar metabolism improving actions may be purified from the above disrupted product of the bacterial cell using a known separation and purification method.
  • the separation and purification method include the method which utilizes solubility such as salt precipitation, organic solvent precipitation, and the like; the method which utilizes the molecular weight difference such as dialysis, ultrafiltration, gel filtration, and the like; the method which utilizes the electric charge difference such as ion exchange chromatography and the like; the method which utilizes the specific bonding such as affinity chromatography and the like; the method which utilizes the hydrophobicity such as hydrophobic chromatography, reversed phase chromatography, and the like; and these methods can be used alone or in combination of two or more methods.
  • the thus obtained bacterial cell disrupted product, bacterial cell extract, or active ingredient containing fraction can be prepared as the lipid metabolism and/or sugar metabolism improver without further treatment or in combination with a carrier or excipient used for foods or beverages or pharmaceutical drugs.
  • additives such as a disintegrator, binder, wetting agent, stabilizer, buffer, lubricant, preservative, surfactant, sweetener, flavor, perfume, acidulant, coloring agent, or the like, may be contained.
  • the dosage form is not limited and can be tablets, capsules, granules, powders, dusts, syrups, dry syrups, solutions, suspensions, emulsifiers, or the like.
  • the above bacterial cell or treated products thereof contained in the lipid metabolism and/or sugar metabolism improver of the present invention are produced from the number of bacterial cells corresponding to, but not limited to, for example, about 10 5 cells/g to about 10 14 cells/g, preferably about 10 8 cells/g to about 10 12 cell/g as the number of bacterial cell before treatment.
  • the lipid metabolism and/or sugar metabolism improver of the present invention comprises, as the active ingredient, the bacterial cell or the treated product thereof as described above, and the bacterial cell or the treated product thereof may be those obtained from one or a plurality of bacterial species.
  • the present invention also provides, the use of CP1563 strain (Accession Number FERM BP-11255), CP1562 strain (Accession Number FERM BP-11379), CP2305 strain (Accession Number FERM BP-11331), or a mutant or bred strain thereof, a treated product thereof, or a mixture thereof, for use in the production of the lipid metabolism and/or sugar metabolism improver of the present invention.
  • the present invention further provides CP1563 strain (Accession Number FERM BP-11255) or CP1562 strain (Accession Number FERM BP-11379), or a mutant or bred strain thereof, which imparts the lipid metabolism and sugar metabolism improving effects.
  • FERM BP-11255 pertinent to the present invention is the accession number for Lactobacillus amylovorus CP1563 strain internationally deposited with the National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary (1-1-1 Higashi, Tsukuba, Ibaraki, Tsukuba Central 6 (305-8566 Japan)) on May 25, 2010 under the Budapest Treaty
  • “FERM BP-11379” is the accession number for Lactobacillus amylovorus CP1562 strain internationally deposited with the same Organism Depositary on Apr. 22, 2011 under the Budapest Treaty
  • “FERM BP-11331” is the accession number for Lactobacillus gasseri CP2305 strain internationally deposited with the same Organism Depositary on Sep. 11, 2007 under the Budapest Treaty.
  • the present invention further provides a food or beverage which comprises the lipid metabolism and/or sugar metabolism improver of the present invention as a food additive.
  • the food or beverage is a functional food or health food for use in improving the lipid metabolism and/or sugar metabolism.
  • the present invention further provides a process for producing a food or beverage having the lipid metabolism and/or sugar metabolism improving effects, which process comprises adding the lipid metabolism and/or sugar metabolism improver of the present invention to a food or beverage.
  • the present invention further provides a pharmaceutical composition for use in preventing, improving, or treating lipid metabolism disorders and sugar metabolism disorders, comprising the lipid metabolism and/or sugar metabolism improver of the present invention as the active ingredient.
  • the lipid metabolism improver obtained as described above is continuously taken, the improving effects on lipid metabolism and sugar metabolism are expected to be achieved and hence the improver can be used for treating or preventing the diseases or disorders associated with the lipid metabolism and sugar metabolism.
  • the lipid metabolism and/or sugar metabolism improver can be used by adding to foods and beverages, pharmaceutical products, or the like.
  • the form of a pharmaceutical composition or a food or beverage is not limited and may be, for example, oral preparations such as tablets, capsules, granules, powders, dusts, syrups, dry syrups, solutions, suspensions, inhalants, or the like, enteral preparations such as suppositories or the like, preparation forms such as drops, injections, or the like. Of these, the oral preparations are preferable.
  • the solution preparations such as solutions, suspensions, or the like, may be a preparation which is dissolved or suspended in water or other suitable medium immediately before taken, and the tablets and granules may have the surface coated by a well-known method.
  • the lipid metabolism improver of the present invention may be formulated into a preparation with the controlled release such as sustained release preparations, delayed release preparations, immediate release preparations, or the like using a technique known in the art.
  • Such a form can be produced in accordance with a routine method by adding, to the ingredients described above, additives commonly used such as an excipient, disintegrator, binder, wetting agent, stabilizer, buffer, lubricant, preservative, surfactant, sweetener, flavor, perfume, acidulant, coloring agent, or the like, depending on the preparation (or dosage) form.
  • additives commonly used such as an excipient, disintegrator, binder, wetting agent, stabilizer, buffer, lubricant, preservative, surfactant, sweetener, flavor, perfume, acidulant, coloring agent, or the like, depending on the preparation (or dosage) form.
  • pharmaceutically acceptable carriers or additives can be added.
  • Examples of the pharmaceutically acceptable carriers and additives include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohols, polyvinylpyrrolidone, carboxy vinyl polymers, sodium alginate, water-soluble dextran, water-soluble dextrin, sodium carboxymethyl starch, pectin, xanthan gum, gum arabic, casein, gelatin, agar, glycerol, propylene glycol, polyethylene glycol, petrolatum, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol, lactose, surfactants acceptable as pharmaceutical additives, as well as artificial cell structures such as liposome, and the like.
  • the content of the lipid metabolism and/or sugar metabolism improver in the pharmaceutical composition or the food or beverage is not particularly limited as long as it imparts the improving effects of lipid metabolism and sugar metabolism, and is, depending on the preparation (or dosage) form, typically within the range of 0.0001 to 99% by mass, preferably 0.001 to 80% by mass, more preferably 0.001 to 75% by mass, in terms of the above bacterial cell or the treated product thereof, and it is desirable to prepare the improver into a form enabling control of a daily dose so that the suitable dose of active ingredient can be taken.
  • the bacterial cell or treated products thereof contained in the lipid metabolism and/or sugar metabolism improver of the present invention are those produced from the number of bacterial cells corresponding to, but not limited to, for example, about 10 5 cells/g to about 10 12 cells/g, preferably about 10 8 cells/g to about 10 12 cell/g, as the number of bacterial cell before treatment.
  • lipid metabolism improver and/or sugar metabolism improver can be added to or contained in the lipid metabolism and/or sugar metabolism improver of the present invention.
  • the other lipid metabolism improver includes, but is not limited to, lipid depressants (e.g., statin drugs, fibrate drugs, eicosapentaenoic acid, docosahexaenoic acid, and the like), and vitamins (e.g., nicotinic acid, vitamin E, and the like).
  • the other sugar metabolism improver includes, but is not limited to, pioglitazone and the like.
  • the pharmaceutical composition or the food or beverage of the present invention may also contain various additives and other various substances used in the production thereof.
  • a substance and additive include various oils and fats (e.g., vegetable oils such as soybean oil, corn oil, safflower oil, olive oil, and the like, animal fats and oils such as beef tallow, sardine oil, and the like), crude drugs (e.g., royal jelly, ginseng, and the like), amino acids (e.g., glutamine, cysteine, leucine, arginine, and the like), polyhydric alcohols (e.g., ethylene glycol, polyethylene glycol, propylene glycol, glycerol, and sugar alcohols including sorbitol, erythritol, xylitol, maltitol, mannitol, and the like), natural polymers (e.g., gum arabic, agar, water-soluble corn fiber, gelatin, xanthan gum, casein, gluten or
  • the lipid metabolism and/or sugar metabolism improver of the present invention may contain, as functional ingredients or additives other than the above active ingredients, for example, taurine, glutathione, carnitine, creatine, coenzyme Q, glucuronic acid, glucuronolactone, capsicium extract, ginger extract, cacao extract, guarana extract, garcinia extracts, theanine, ⁇ -aminobutyric acid, capsaicin, capsiate, various organic acids, flavonoids, polyfenols, catechins, xanthine derivatives, non-digestible oligosaccharides such as fructooligosaccharide, and the like, polyvinylpyrrolidone, and the like.
  • functional ingredients or additives other than the above active ingredients, for example, taurine, glutathione, carnitine, creatine, coenzyme Q, glucuronic acid, glucuronolactone, capsicium extract, ginger extract, cacao extract, guaran
  • the subjects (or patients) who are administered with or ingests the lipid metabolism improver and the pharmaceutical composition or food or beverage comprising the improver of the present invention are vertebrates, in particular, mammals such as human, primates (e.g., monkey, chimpanzee, and the like), livestock animals (e.g., cow, horse, pig, sheep, and the like), companion animals (e.g., dog, cat, and the like), experimental animals (e.g., mouse, rat, and the like), and further reptiles and birds, preferably human.
  • mammals such as human, primates (e.g., monkey, chimpanzee, and the like), livestock animals (e.g., cow, horse, pig, sheep, and the like), companion animals (e.g., dog, cat, and the like), experimental animals (e.g., mouse, rat, and the like), and further reptiles and birds, preferably human.
  • the dose or intake amount of the lipid metabolism and/or sugar metabolism improver of the present invention varies depending on the subject's age and body weight, administration or intake route, dose or intake frequency, severity of the lipid metabolism disorder or the like, and can be changed in a wide range by the discretion of a person skilled in the art to achieve the intended actions.
  • the bacterial cell or the treated product thereof contained in the lipid metabolism and/or sugar metabolism improver is desirably administered in an amount of typically about 10 6 cells to about 10 12 cells, preferably about 10 7 cells to about 10 11 cells, per kg of body weight when represented by the bacterial cell amount before treatment.
  • the lipid metabolism and/or sugar metabolism improver, the pharmaceutical composition, and the food or beverage of the present invention are very safe and the intake amount can be increased.
  • the daily intake amount may be taken once, or in several divided times.
  • the frequency of administration or intake is not particularly limited and can suitably be selected in accordance with various conditions such as administration or intake route, subject's age and body weight, the severity of lipid metabolism disorder or sugar metabolism disorder, the presence of disease or disorder onset caused by the lipid metabolism disorder or sugar metabolism disorder, intended effects (treatment, prevention, or the like), and the like.
  • the administration or intake route of the lipid metabolism and/or sugar metabolism improver, the pharmaceutical composition, and the food or beverage of the present invention includes, but is not particularly limited to, oral administration or intake, or parenteral administration (e.g., intrarectal, subcutaneous, intramuscular, and intravenous administrations), and the like, preferably oral administration or intake.
  • oral administration or intake or parenteral administration (e.g., intrarectal, subcutaneous, intramuscular, and intravenous administrations), and the like, preferably oral administration or intake.
  • the lipid metabolism and/or sugar metabolism improver, the pharmaceutical composition, and the food or beverage of the present invention have the actions of reducing a subject's lipid in blood, promoting the metabolisms of subcutaneous fat and/or visceral fat, and suppressing the body weight gain, as the lipid metabolism improver.
  • the lipid metabolism improver, the pharmaceutical composition, and the food or beverage of the present invention have the effects of normalizing the lipid metabolism by reducing a subject's total cholesterol, LDL-cholesterol, triglyceride, arteriosclerotic index and/or visceral fat, and/or elevating HDL-cholesterol and/or adiponectin.
  • the lipid metabolism and/or sugar metabolism improver, the pharmaceutical composition, and the food or beverage of the present invention have the actions of preventing, improving, or treating diseases such as hyperglycemia, noninsulin dependent diabetes mellitus, or the like by improving the insulin resistance, as the sugar metabolism improver.
  • the lipid metabolism and/or sugar metabolism improver, the pharmaceutical composition, and the food or beverage of the present invention show good preventive, improving and therapeutic effects on the diseases or disorders associated with the lipid metabolism and sugar metabolism. In addition, they are very safe and easily taken continuously for an extended period of time.
  • the term “diseases or disorders associated with the lipid metabolism” refers to diseases, disorders, symptoms or syndromes caused by the lipid metabolism abnormality.
  • diseases or disorders associated with the lipid metabolism include, but are not limited to, arteriosclerosis, hyperlipidemia, steatohepatitis, obesity, metabolic syndrome, circulatory system diseases (e.g., myocardial infarction, cerebral infarction, and the like).
  • diabetes mellitus such as dyslipidemia, hypertension, endodermal impairment, inflammatory atherosclerosis, and the like in addition to non-insulin-dependent diabetes mellitus and hyperglycemia.
  • the food or beverage of the present invention contains the lipid metabolism and/or sugar metabolism improver as described above.
  • the food or beverage encompasses beverages.
  • the food or beverage comprising the lipid metabolism and/or sugar metabolism improver of the present invention encompasses all foods or beverages to which the above lipid metabolism and/or sugar metabolism improver can be added, in addition to the health foods or beverages, functional foods or beverages, foods or beverages for specified health use, and the like, which enhance health by the lipid metabolism improving action and sugar metabolism improving action.
  • the “functional food or beverage” of the present invention means a food or beverage having a certain function on the living body, and encompasses the so-called health foods or beverages in general such as foods and beverages with health claims including foods and beverages for specified health use (including qualified “foods for specified health use”) and foods and beverages with nutrient function claims, foods or beverages for special dietary uses, nutrition supplement foods or beverages, health supplement foods or beverages, supplements (e.g., those in various forms such as tablets, coated tablets, sugar coated tablets, capsules, solutions, or the like), food or beverage for beauty (e.g., diet food or beverage, and the like), and the like.
  • the functional food or beverage of the present invention also encompasses the health foods or beverages to which the health claim based on the food standard by the Codex (the Joint FAO/WHO Food Standards Commission) is applicable.
  • foods or beverages include liquid foods such as intertubular enteral nutrients and the like; health foods or beverages and nutrition supplement foods or beverages in the form of preparation forms such as tablet candies, tablets, chewable tablets, dusts, powders, capsules, granules, drinks, and the like; tea drinks such as green teas, oolong tea, English teas, and the like; drinks such as soft drinks, jelly beverages, sports drinks, milk beverages, carbonated drinks, vegetable drinks, fruit juice drinks, fermented vegetable drinks, fermented fruit juice drinks, fermented milk beverages (yogurts and the like), lactic acid bacterial beverages, milk-based drinks (coffee-flavored milk, fruit-flavored milk, and the like), powder drinks, cocoa drinks, milk as well as purified water, and the like: spreads such as butter, jams, Furikake (dried food sprinkles), margarine, and the like; mayonnaise, shortening, custard cream, dressings, breads, rice, noodles, pastas, misosoup, soybean curd, yogurt
  • the food or beverage of the present invention can contain other food materials used in the production of the food or beverage, various nutrients, various vitamins, minerals, dietary fibers, various additives (e.g., taste components, sweeteners, acidulants such as organic acids, stabilizers, flavors) or the like, in addition to the above lipid metabolism and/or sugar metabolism improver, and can be produced in accordance with a routine method.
  • various additives e.g., taste components, sweeteners, acidulants such as organic acids, stabilizers, flavors
  • the addition amount of lipid metabolism and/or sugar metabolism improver can suitably be determined by those skilled in the art in consideration with the preparation form and required flavors or textures of the food or beverage.
  • the addition amount of the lipid metabolism and/or sugar metabolism improver is suitable when the total amount of the bacterial cell or the treated product thereof to be added to the lipid metabolism and/or sugar metabolism improver is typically 0.0001 to 99% by mass, preferably 0.001 to 80% by mass, more preferably 0.001 to 75% by mass, when represented by the bacterial cell amount before treatment.
  • the lipid metabolism and/or sugar metabolism improver of the present invention is very safe and hence the addition amount to the food or beverage can further be increased.
  • the improver into a form enabling control of a daily dose so that the desirable intake amount of the lipid metabolism and/or sugar metabolism improver can be consumed.
  • a prevention method and improving method for the diseases or disorders associated with the lipid metabolism and/or sugar metabolism using the food or beverage of the present invention are provided, when the food or beverage of the present invention is consumed in the form which enables control of the desirable intake amount of the lipid metabolism and/or sugar metabolism improver of the present invention.
  • the lipid metabolism and/or sugar metabolism improver of the present invention may be contained in foods or beverages by any suitable method available to those skilled in the art.
  • the lipid metabolism and/or sugar metabolism improver of the present invention is formulated into a liquid, gel, solid, powder or granular preparation, and subsequently added to a food or beverage.
  • the lipid metabolism and/or sugar metabolism improver of the present invention may be directly mixed with or dissolved in raw materials of the food or beverage.
  • the lipid metabolism and/or sugar metabolism improver of the present invention may be coated on, covered over, infiltrated into, or sprayed onto a food or beverage.
  • the lipid metabolism and/or sugar metabolism improver of the present invention may be homogeneously dispersed or unevenly distributed in a food or beverage.
  • a capsule comprising the lipid metabolism and/or sugar metabolism improver of the present invention may be prepared.
  • the lipid metabolism and/or sugar metabolism improver of the present invention may be enveloped with an edible film, edible coating agent, or the like. Further, the lipid metabolism and/or sugar metabolism improver of the present invention may be molded to the shape of tablets or the like after adding a suitable excipient or the like.
  • the food or beverage comprising the lipid metabolism and/or sugar metabolism improver of the present invention may further be processed, and such a processed product is also encompassed in the scope of the present invention.
  • additives routinely used in foods and beverages may be used in the production of the food or beverage of the present invention.
  • the additives include, but are not limited to, color formers (sodium nitrite and the like), coloring agents (gardenia pigment, red 102 , and the like), perfumes (orange perfume and the like), sweeteners (stevia, aspartame, and the like), preservatives (sodium acetate, sorbic acid, and the like), emulsifiers (sodium chondroitin sulfate, propylene glycol fatty acid esters, and the like), antioxidants (disodium EDTA, vitamin C, and the like), pH adjusting agents (citric acid and the like), synthetic seasonings (sodium inosinate and the like), thickeners (xanthan gum and the like), raising agents (calcium carbonate and the like), defoaming agents (calcium phosphate), and the like, binders (sodium polyphosphate and the like), nutri
  • the food or beverage of the present invention has the lipid metabolism and sugar metabolism improving actions, and thus has good preventing and improving actions on the diseases or disorders associated with the lipid metabolism and sugar metabolism and is very safe without concerns of adverse effects. Further, the lipid metabolism and/or sugar metabolism improver of the present invention has good flavor and does not affect flavors of any foods or drinks when added to various foods or drinks, and thr this reason the obtained food or beverage can be easily taken continuously for an extended period of time and expected to have good preventing and improving effects on the diseases or disorders associated with the lipid metabolism.
  • lipid metabolism and/or sugar metabolism improver of the present invention can be added not only to foods or drinks for human consumption but also to feeds for livestock, racehorses, companion animals, and the like.
  • feeds for livestock, racehorses, companion animals, and the like are equally applicable to the feed, since the feed is substantially the same as the food or beverage except that it is for other than human consumption.
  • the cell strain of each lactic acid bacterium was inoculated from frozen stocks onto plate medium, and then the pre-preincubation, preincubation and main incubation were carried out (5 ml ⁇ 40 ml ⁇ 2 L) using liquid medium.
  • Table 1 shows the bacterial species, bacterial strains, medium and incubation temperatures used. Additionally, the inoculum concentration was 1% of each liquid medium weight and the incubation was carried out for 18 hours (see Table 2 for the medium used and incubation temperatures).
  • the culture was centrifuged at 12000 g at 10° C. for 7 minutes, and the supernatant was removed. Ion exchange water was added, the culture was centrifuged in the same manner, and the freeze-dried bacterial cell was dispersed using a mill (TESCOM), thereby obtaining a bacterial cell powder.
  • TESCOM freeze-dried bacterial cell powder
  • Two g of the bacterial cell powder was suspended in 500 ml of a 0.5 mol/l potassium hydroxide-ethanol solution (KANTO KAGAKU) and then disrupted ultrasonically for 2 minutes (power output 40%, max 750 W, probe-type, VC-750 (TOKYO RIKAKIKAI CO., LTD.)).
  • the treated solution was transferred to a 500 ml wide mouthed medium bottle with a red cap (heat resistance, SANSYO), which was then hermetically closed.
  • the bottle was heated in boiling water at 100° C. for 1 hour in the stationary state, and then cooled in running water.
  • Concentrated hydrochloric acid WAKO PURE CHEMICAL INDUSTRY, Ltd. was added to the cooled bacterial solution to adjust pH to be 2 or less.
  • the liquid part was concentrated to about 50 ml in a water bath at 40° C. using a rotary evaporator (NVC-2100, TOKYO RIKAKIKAI CO., LTD.).
  • the concentrated liquid was divided into two equal amounts, respectively placed in a 50 ml glass centrifuge tube (AGC Techno Glass, Co., Ltd.), diethyl ether (Wako Pure Chemical Industry, Ltd.) of the equal amount was added thereto and stirred for 1 hour using a shaker (200 rpm/min, R-30, TIETECH Co., Ltd.), thereby separating and collecting the upper layer.
  • the same procedure was carried out 4 times in total, and the fraction separated and collected was dried to solidify using a rotary evaporator.
  • the fraction was thoroughly dried to solidify by spraying nitrogen gas, then dissolved in 500 ⁇ L of a special grade DMSO (WAKO PURE CHEMICAL INDUSTRY, Ltd.) and preserved at ⁇ 80° C. in a brown vial (cold resistance, SANSYO).
  • DMSO a special grade DMSO
  • the fatty acid concentration in diethyl ether was measured using NEFA C-Test Wako (WAKO PURE CHEMICAL INDUSTRY, Ltd.).
  • Cultured cell CV-1 derived from the kidney of an African green monkey was prepared to a concentration of 5 ⁇ 10 4 cells/ml, suspended in DMEM medium containing 10% (v/v) FBS (SIGMA), and cultured at 37° C. for 24 hours under 5% CO 2 in air (v/v) in a concentration of 500 ⁇ L/well using a flat 24-well plate (Corning). Twenty four hours later, 80 to 90% confluence was microscopically confirmed to have reached, and subsequently the transfection was carried out by the following procedure.
  • Plasmid pM-PPAR ⁇ 0.16 which comprises a DNA fragment encoding a chimeric protein comprising PPAR ⁇ ligand binding domain (derived from human) and GAL-4DNA binding domain (derived from yeast), and p4xUASg-tk-luc 0.16 ⁇ g, which is a luc (derived from sea-firefly) reporter gene plasmid designed to receive expression control by the above chimeric protein, and pRL-CMV 0.016 ⁇ g, which is a luc (derived from Renilla) expression plasmid having a viral expression promoter with a fixed expression amount in cells, were added to 25 ⁇ l of the reduced serum medium Opti-MEM (Invitrogen) and mixed, to which 4 ⁇ l of PLUS Reagent (Invitrogen) was added and allowed to stand at room temperature for 15 minutes.
  • Opti-MEM Invitrogen
  • Lipofectamine Reagent (Invitrogen) 1 ⁇ l and Opti-MEM 25 ⁇ l were added thereto, allowed to stand at room temperature for 15 minutes, and subsequently Opti-MEM 200 ⁇ l was added thereto.
  • the obtained solution 250 ⁇ l was added to the cultured CV-1 cell washed with Opti-MEM and incubated at 37° C. for 3 hours. After incubation, the medium was discarded and 1 ml of DMEM medium containing 10% (v/v) FBS was added.
  • Evaluation samples were prepared as follows. The diethyl ether extract of each lactic acid bacterium was diluted with Opti-MEM so that the final concentration of DMSO is 0.1%. GW7647 (SIGMA) was used as the positive control and DMSO was used as the negative control of the PPAR ⁇ ligand. The concentration of the lactic acid bacterium extract sample was 2.5 ⁇ M (in terms of fatty acid), and the concentration of GW7647 was 10 nM, at the time of assay.
  • the cryopreserved sample 30 ⁇ L was added to a 96-well white microplate (PerkinElmer), and the luminescence intensities (590 nm and 645 nm) were measured using Dual-GloTM Luciferase Assay System (Promega), whereby the PPAR ⁇ ligand ability was measured.
  • the activity is shown in the relative value when the negative control is 0 and the positive control is 100.
  • the PPAR ⁇ activity value is 70 or more, more preferably 80 or more, 90 or more, 95 or more, 100 or more, 120 or more, 140 or more.
  • NCI9040 strain having the highest activity in Patent Document 5 Japanese Patent Publication (Kokai) No. 2007-284360 shows only about 67% activation ability compared with that of Lactobacillus amylovorus CP1563 strain.
  • Cultured cell CV-1 derived from the kidney of an African green monkey was prepared to a concentration of 5 ⁇ 10 4 cells/ml, suspended in DMEM medium containing 10% (v/v) FRS (SIGMA), and cultured at 37° C. for 24 hours under 5% CO 2 in air (v/v) in a concentration of 500 ⁇ L/well using a flat 24-well plate (Corning). Twenty four hours later, 80 to 90% confluence was microscopically confirmed to have reached and subsequently the transfection was carried out by the following procedure.
  • Plasmid pM-PPAR ⁇ 0.16 ⁇ g which comprises a DNA fragment encoding a chimeric protein comprising PPAR ⁇ ligand binding domain (derived from human) and GAL-4DNA binding domain (derived from yeast), and p4xUASg-tk-luc 0.16 ⁇ g, which is a luc (derived from sea-firefly) reporter gene plasmid designed to receive expression control by the above chimeric protein, and pRL-CMV 0.016 ⁇ g, which is a luc (derived from Renilla) expression plasmid having a viral expression promoter with a fixed expression amount in cells, were added to 25 ⁇ l of reduced serum media Opti-MEM (Invitrogen) and mixed, to which 4 ⁇ l of PLUS Reagent (Invitrogen) was added and allowed to stand at room temperature for 15 minutes.
  • Opti-MEM Invitrogen
  • PLUS Reagent Invitrogen
  • Opti-MEM 200 ⁇ l was added thereto.
  • the obtained solution 250 ⁇ l was added to the cultured CV-1 cell washed with Opti-MEM and incubated at 37° C. for 3 hours. After incubation, the medium was discarded and 1 ml of DMEM medium containing 10% (v/v) FBS was added.
  • Samples to be evaluated were prepared as follows. Of the lactic acid bacteria strains listed in Table 1, diethyl ether extracts of Lactobacillus amylovorus CP1563 strain, Bifidobacterium infantis No. 23 strain, Bifidobacterium breve No. 22 strain, Lactobacillus gasseri CP2305 strain, Bifidobacterium adolescentis No. 20 strain, Bifidobacterium catenulatum No. 24 strain, Lactococcus lactis No. 14 strain and Bifidobacterium longum No. 21 strain, which were 8 bacterium strains having the comparatively high PPAR ⁇ activation ability, were diluted with Opti-MEM so that the final concentration of DMSO was 0.1%.
  • Troglitazone (Wako Pure Chemical Industry, Ltd.) was used as the positive control and DMSO was used as the negative control of the PPAR ⁇ ligand.
  • the concentration of lactic acid bacterium extract sample was 2.5 ⁇ M (in terms of fatty acid) and the concentration of Troglitazone was 1 nM, at the time of assay.
  • the cryopreserved sample 30 ⁇ L was added to a 96-well white microplate (PerkinElmer), and the luminescence intensities (590 nm and 645 nm) were measured using Dual-GloTM Luciferase Assay System (Promega), whereby the PPAR ⁇ ligand ability was measured.
  • the activity is shown in the relative value when the negative control is 0 and the positive control is 100.
  • Lactoccus lactis No. 14 strain some bacterial strains with a comparatively high PPAR ⁇ activity do not have the PPAR ⁇ activity. Accordingly, the fact that some bacteria such as Lactobacillus amylovorus CP1563 strain according to the present invention activate both PPAR ⁇ and PPAR ⁇ is a remarkable finding.
  • Lactobacillus amylovorus CP1563 strain was taken and isolated from human feces. The bacterial species was identified by the 16S rDNA nucleotide sequence analysis and phenotype observation.
  • the lactic acid bacterium was incubated at 37° C. for 18 hours using self-prepared food grade lactic acid bacterium medium and collected by centrifugal separation. After washing with deionized water and collecting, the cells were suspended again in a suitable amount of water and sterilized at 90° C. The sterilized suspension was disrupted using a DYNO-MILL under the following conditions.
  • DYNO-MILL disruptor Multi-lab 0.6L, SHINMARU ENTERPRISES CORPORATION
  • Circumferential speed 14.0 m/s
  • Disrupting tank temperature 15° C.
  • the average major axis of destructed bacterial cells in the lactic acid bacterium suspension was reduced to 68% of before treatment (2.77 ⁇ 1.89 ⁇ m) by the above disruption (or destruction) treatment. After disruption, the suspension was freeze-dried, thereby obtaining a disrupted lactic acid bacterium freeze-dried powder.
  • the ingredients were mixed in the amounts indicated in Table 4 to produce lactic acid bacterium containing high fat diets.
  • mice C57BL/6 male mice (5 weeks of age) were fed with the high fat diet (control diet) prepared as above for 1 week before examination and used as obese model mice. Subsequently, the mice were fed with the Lactobacillus amylovorus CP1563 strain disrupted bacterial cell containing high fat diet (containing 0%, 0.25%, 0.5% or 1.0%, by weight) for 6 weeks. The mice were kept by the pair feeding method to adjust the food intake amount of each group to be equal. Blood samples were collected at the completion of experiment, and HDL cholesterol value was measured to investigate the effect of lactic acid bacteria. In addition, the arteriosclerotic index was determined by the following formula:
  • Arteriosclerotic index (total cholesterol ⁇ HDL cholesterol) ⁇ HDL cholesterol
  • FIG. 1 HDL-cholesterol
  • FIG. 2 arteriosclerotic index
  • the above obese model mice were fed with the Lactobacillus amylovorus CP1563 strain disrupted bacterial cell containing high fat diet (containing 0% or 1%, by weight) for 3 months. Then, the obese model mice were measured for HDL-cholesterol, LDL-cholesterol, triglyceride, arteriosclerotic index, high molecular adiponectin, and visceral fat weight.
  • CP1563 strain was cultured at 37° C. for 18 hours using self-prepared food grade lactic acid bacterium medium and collected by the filter concentration.
  • the concentrated liquid was sterilized at 90° C. and freeze-dried, thereby obtaining a lactic acid bacterium freeze-dried powder.
  • the bacterial cell was disrupted using a planetary ball mill under the following conditions.
  • Circumferential speed 14.0 m/s
  • the CP1563 strain disrupted bacterial cell whose average major axis was reduced to 47% of before treatment (2.77 ⁇ 1.30 ⁇ m) was obtained by the above disruption (destruction) treatment.
  • Diagnose and physical examination were carried out 0, 8 and 12 weeks later from the intake, and the fat measurement by a CT scan was carried out 0 and 12 weeks later from the intake.
  • FIGS. 4 , A to F The results are shown in FIGS. 4 , A to F.
  • the body weight and BMI were significantly reduced when compared with before the intake by the administration of CP1563 strain disrupted bacterial cell, and the body fat rate and BMI were significantly reduced compared with the control groups ( FIGS. 4B , 4 C).
  • the body temperature was significantly reduced and suppressed when compared with the control groups ( FIG. 4D ).
  • FIG. 4E the subcutaneous fat area was significantly reduced when compared with before initiating the intake by the administration of the CP1563 strain disrupted bacterial cell.
  • the bacterial cells described herein can be used as the bacterial cell to produce the composition for improving the lipid metabolism and/or sugar metabolism. Further, it is confirmed that the bacterial cells described herein can be used as the bacterial cell to produce the composition for improving or preventing the lipid metabolism and/or sugar metabolism.
  • the bacterial cells described herein can be used as the bacterial cell to produce the composition for reducing the subcutaneous fat and/or visceral fat, and can be used as the bacterial cell to produce the composition for preventing the subcutaneous accumulation of fat and/or visceral fat.
  • Tanita body fat analyzer TBF-310 was used for the measurement.
  • CT scanner system (CT-W450) of Hitachi Medical Corporation was used.
  • the lipid metabolism and/or sugar metabolism improver of the present invention can improve the lipid metabolism and/or sugar metabolism on the human test, and is hence useful for preventing, improving or treating the diseases or disorders associated with such metabolism abnormalities.
  • the present invention provides the lactic acid bacterium, Lactobacillus amylovorus CP1563 strain, which has not only high PPAR ⁇ activation ability but also high PPAR ⁇ activation ability.
  • the lactic acid bacteria of the present invention promote the fat burning by the PPAR ⁇ activation and increase the expression of adiponectin, which is a beneficial factor secreted from the fat cells by the PPAR ⁇ activation, and thus they can be used for preventing or treating various diseases or disorders. Consequently, the present invention is useful in the fields of pharmaceutical products, food or beverages, livestock farming, and the like.
  • FERM BP-11255 is the accession number for Lactobacillus amylovorus CP1563 strain internationally deposited with the National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary (1-1-1 Higashi, Tsukuba, Ibaraki, Tsukuba Central 6 (305-8566 Japan)) on May 25, 2010 under the Budapest Treaty,
  • FERM BP-11379 is the accession number for Lactobacillus amylovorus CP1562 strain internationally deposited with the National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary (1-1-1 Higashi, Tsukuba, Ibaraki, Tsukuba Central 6 (305-8566 Japan)) on Apr. 22, 2011 under the Budapest Treaty, and
  • FERM BP-11331 is the accession number for Lactobacillus gasseri CP2305 strain internationally deposited with the National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary (1-1-1 Higashi, Tsukuba, Ibaraki, Tsukuba Central 6 (305-8566 Japan)) on Sep. 11, 2007 under the Budapest Treaty.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
US14/363,150 2011-12-07 2012-12-06 Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof Abandoned US20140322172A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011268313 2011-12-07
JP2011-268313 2011-12-07
JP2012-067187 2012-03-23
JP2012067187 2012-03-23
PCT/JP2012/081597 WO2013084971A1 (fr) 2011-12-07 2012-12-06 Stimulant du metabolisme des lipides et/ou du metabolisme du sucre contenant une bacterie d'acide lactique ou produit de traitement associe

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/081597 A-371-Of-International WO2013084971A1 (fr) 2011-12-07 2012-12-06 Stimulant du metabolisme des lipides et/ou du metabolisme du sucre contenant une bacterie d'acide lactique ou produit de traitement associe

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/408,722 Division US10245291B2 (en) 2011-12-07 2017-01-18 Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof

Publications (1)

Publication Number Publication Date
US20140322172A1 true US20140322172A1 (en) 2014-10-30

Family

ID=48574329

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/363,150 Abandoned US20140322172A1 (en) 2011-12-07 2012-12-06 Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof
US15/408,722 Active US10245291B2 (en) 2011-12-07 2017-01-18 Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/408,722 Active US10245291B2 (en) 2011-12-07 2017-01-18 Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof

Country Status (11)

Country Link
US (2) US20140322172A1 (fr)
EP (1) EP2789340A4 (fr)
JP (3) JP5690416B2 (fr)
KR (2) KR20150000867A (fr)
CN (1) CN104010648A (fr)
AU (1) AU2012349340B2 (fr)
CA (1) CA2861533C (fr)
MY (1) MY172363A (fr)
PH (1) PH12014501254A1 (fr)
SG (2) SG11201402993XA (fr)
WO (1) WO2013084971A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013084971A1 (fr) * 2011-12-07 2013-06-13 カルピス株式会社 Stimulant du metabolisme des lipides et/ou du metabolisme du sucre contenant une bacterie d'acide lactique ou produit de traitement associe
WO2013130773A2 (fr) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions de microbiota et leurs procédés associés
WO2014077365A1 (fr) * 2012-11-16 2014-05-22 カルピス株式会社 Agent soulageant les troubles intestinaux induits par le stress comprenant une souche spécifique de lactobacillus gasseri ou produit de traitement associé
EP3016511B1 (fr) * 2013-07-02 2019-10-09 Austrianova Singapore Pte Ltd. Procédé de lyophilisation de cellules encapsulées, compositions convenant à la congélation de cellules encapsulées, et utilisation de telles compositions
JP6557605B2 (ja) * 2013-11-07 2019-08-07 サントリーホールディングス株式会社 乳酸菌を含む腸管バリア機能亢進剤
EP3165599A4 (fr) * 2014-05-29 2017-12-27 Nitto Pharmaceutical Industries, Ltd. Nouvelle bactérie d'acide lactique et composition comprenant cette bactérie d'acide lactique
EP3881680A1 (fr) 2014-10-31 2021-09-22 Pendulum Therapeutics, Inc. Procédés et compositions se rapportant à un traitement microbien de troubles
JP5703513B1 (ja) * 2014-11-05 2015-04-22 沖縄ハム総合食品株式会社 新規乳酸菌株及びその乳酸菌株による発酵組成物及び醗酵エキス
BR112018001187B1 (pt) 2015-07-20 2022-02-15 Quorum Innovations, Llc Composição bacteriana, seus usos, método para melhorar condição de pele e método para desinfecção de uma superfície
JP2017108679A (ja) * 2015-12-16 2017-06-22 株式会社 オヴァールリエゾン チョコレート菓子
JP6961339B2 (ja) * 2015-12-18 2021-11-05 アサヒ飲料株式会社 微生物菌体含有飲料
EP3479837B1 (fr) * 2016-06-30 2023-09-06 Asahi Group Holdings, Ltd. Composition améliorant l'anémie rénale
JP6923883B2 (ja) * 2016-06-30 2021-08-25 アサヒグループホールディングス株式会社 栄養状態改善に使用するための組成物
EP3675882A4 (fr) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. Methodes et compositions pour le traitement de troubles associés au microbiome
KR101935762B1 (ko) * 2018-08-25 2019-01-04 김민재 동물 투약 보조용 조성물 및 이의 제조방법
JP6480630B1 (ja) * 2018-09-26 2019-03-13 アサヒグループホールディングス株式会社 脂肪蓄積抑制剤および血中脂質改善剤
CN109666615B (zh) * 2019-02-20 2021-03-19 无限极（中国）有限公司 一种益生菌组合物及其应用
IL288799B1 (en) * 2019-06-11 2024-04-01 Advance Pharmaceutical Inc Superoxide soluble fiber components
KR102229090B1 (ko) * 2019-07-26 2021-03-19 (주)성운파마코피아 락토바실러스 가세리 swpm102를 포함하는 허혈성 뇌질환의 예방, 개선 또는 치료용 조성물
JP7364390B2 (ja) * 2019-08-19 2023-10-18 株式会社明治 糖代謝改善用組成物
KR102271528B1 (ko) * 2020-01-03 2021-07-02 경희대학교 산학협력단 유산균 파쇄체로 코팅된 스테비아 분말을 포함하는 비만 또는 당뇨 예방 및 치료용 조성물
CN111235058B (zh) * 2020-02-20 2022-11-15 江苏微康生物科技有限公司 一种具有修复紫外损伤、缓解炎症、预防皮肤光老化作用的短双歧杆菌及其制备方法和应用
KR102128098B1 (ko) * 2020-03-23 2020-06-30 주식회사 종근당바이오 락토바실러스 델브루키 subsp. 락티스 CKDB001 균주, 및 이를 포함하는 비알코올성 지방간의 예방, 개선, 또는 치료용 조성물
KR102257130B1 (ko) * 2020-06-16 2021-05-28 주식회사 엠디헬스케어 락토바실러스 파라카세이 유래 소포를 포함하는 신경질환 또는 정신질환 예방 또는 치료용 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61109729A (ja) 1984-11-05 1986-05-28 Advance Res & Dev Co Ltd コレステロ−ル低下剤
JPS61271223A (ja) * 1985-05-24 1986-12-01 Biofuerumin Seiyaku Kk 血中脂質改善剤
JP3359827B2 (ja) * 1996-10-29 2002-12-24 株式会社ヤクルト本社 脂質代謝改善剤及びそれを含有する食品
EP0856259B1 (fr) 1996-12-23 1998-08-12 SITIA-YOMO S.p.A. Composition pour l'usage dans l'alimentation comprenant de bactéries vivantes lactiques lyophisées
JP3777296B2 (ja) 2000-09-04 2006-05-24 明治製菓株式会社 乳酸菌によるコレステロールの低減若しくは除去方法
JP2003306436A (ja) 2002-02-15 2003-10-28 Snow Brand Milk Prod Co Ltd 血清コレステロール上昇抑制剤
AU2003256419A1 (en) * 2002-08-21 2004-03-11 Merck & Co., Inc. Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
JP2007504285A (ja) * 2003-01-17 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体
JP5025930B2 (ja) * 2005-09-13 2012-09-12 株式会社桃屋 ラクトバチルス・プランタラムの菌体を有効成分とする体脂肪率低減剤
JP4336992B2 (ja) 2006-01-20 2009-09-30 日清食品ホールディングス株式会社 血中コレステロール低減作用を有する新規乳酸菌
JP2007284260A (ja) * 2006-04-12 2007-11-01 Ｓｕｍｃｏ Ｔｅｃｈｘｉｖ株式会社 シリコン単結晶の製造方法
JP2007284360A (ja) 2006-04-13 2007-11-01 Mitsukan Group Honsha:Kk 乳酸菌由来のｐｐａｒ依存的遺伝子転写活性化組成物
JP5314421B2 (ja) * 2006-05-31 2013-10-16 株式会社明治 免疫調節活性の高い乳酸菌の培養法
JP5247012B2 (ja) 2006-07-25 2013-07-24 雪印メグミルク株式会社 脂肪肝抑制剤
ITMI20062363A1 (it) * 2006-12-06 2008-06-07 Aat Advanced Analytical Technology Ceppi di lattobacilli probiotici che persistono nell'intestino e ne modulano i recettori di mucosa
JP2008214253A (ja) * 2007-03-02 2008-09-18 Snow Brand Milk Prod Co Ltd 内臓脂肪減少剤
EP2506863A4 (fr) * 2009-12-04 2013-07-17 Technologie Biolactis Inc Procédé de régulation de ppar, voies en rapport avec l'obésité et leur impact métabolique connexe
WO2011155518A1 (fr) * 2010-06-08 2011-12-15 カルピス株式会社 Agent améliorant le métabolisme des lipides
JP2012067187A (ja) 2010-09-24 2012-04-05 Riso Kagaku Corp 非水系インクジェットインク
WO2013084971A1 (fr) * 2011-12-07 2013-06-13 カルピス株式会社 Stimulant du metabolisme des lipides et/ou du metabolisme du sucre contenant une bacterie d'acide lactique ou produit de traitement associe
WO2014077365A1 (fr) 2012-11-16 2014-05-22 カルピス株式会社 Agent soulageant les troubles intestinaux induits par le stress comprenant une souche spécifique de lactobacillus gasseri ou produit de traitement associé
JP2014165231A (ja) * 2013-02-22 2014-09-08 Fujitsu Ltd 電子部品ユニット及び固定構造

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Kondo et al. Biosci. Biotechnol. Biochem., 2010, 74(8):1656-1661. *
Namba et al. Infection and Innunity, 1981, 31(2):580-583. *
Temmerman et al. Applied and Environmental Microbiology, 2003, 220-226. *
Tursi et al. Int J Colorectal Dis., 2007, 22:1103-1108. *

Also Published As

Publication number Publication date
PH12014501254A1 (en) 2014-09-08
JP2014237705A (ja) 2014-12-18
WO2013084971A1 (fr) 2013-06-13
KR101809695B1 (ko) 2017-12-15
MY172363A (en) 2019-11-21
AU2012349340B2 (en) 2015-11-05
JP2015108010A (ja) 2015-06-11
JPWO2013084971A1 (ja) 2015-04-27
EP2789340A4 (fr) 2015-07-22
AU2012349340A1 (en) 2014-07-24
EP2789340A1 (fr) 2014-10-15
US10245291B2 (en) 2019-04-02
US20170119828A1 (en) 2017-05-04
SG11201402993XA (en) 2014-09-26
CA2861533A1 (fr) 2013-06-13
JP5690435B2 (ja) 2015-03-25
KR20150000867A (ko) 2015-01-05
SG10201609078TA (en) 2016-12-29
KR20170104629A (ko) 2017-09-15
JP5690416B2 (ja) 2015-03-25
CA2861533C (fr) 2020-07-14
CN104010648A (zh) 2014-08-27
JP6165185B2 (ja) 2017-07-19

Similar Documents

Publication Publication Date Title
US10245291B2 (en) Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof
US9468657B2 (en) Lactic acid bacterium agent for improving lipid metabolism
JP5923238B2 (ja) 迷走神経活性化剤
EP2478910B1 (fr) Agent anti-obésité, aliment ou boisson anti-obésité, agent d'amélioration de tolérance au glucose et aliment ou boisson pour l'amélioration de la tolérance au glucose
EP3479837B1 (fr) Composition améliorant l'anémie rénale
JP6923883B2 (ja) 栄養状態改善に使用するための組成物
JP5950993B2 (ja) 迷走神経活性化剤
EP3479836B1 (fr) Composition facilitant la régénération du cartilage
JP7430312B2 (ja) 腸内短鎖脂肪酸産生促進用組成物及びこれを含む飲食品
AU2015201076B2 (en) Lipid metabolism-improving agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: CALPIS CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAKAMURA, FUTOSHI;ASHIDA, NOBUHISA;ISHIDA, YU;AND OTHERS;SIGNING DATES FROM 20140507 TO 20140509;REEL/FRAME:033039/0872

AS Assignment

Owner name: ASAHI GROUP HOLDINGS, LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CALPIS CO., LTD.;REEL/FRAME:037501/0292

Effective date: 20151231

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION